IPCA, CDRI to develop anti-malarial drugs based on Artemisinin
IPCA Laboratories and Central Drug Research Institute (CDRI) will develop a synthetic substitute of anti-malarial drugs.
By PTI |
MUMBAI: Drug maker IPCA Laboratories on Monday said together with Central Drug Research Institute (CDRI) it will develop a synthetic substitute of anti-malarial drugs, based on Artemisinin.
The company has entered into a collaborative-cum-license agreement with CDRI for further developing its compound 99/411, a synthetic substitute for drugs based on Artemisinin derived from the plant artemisia annua, IPCA informed the BSE.
It would be a major break through in cost effective treatment of falciparum malaria and multi-drug resistant falciparum malaria in clinical practice, IPCA said.
The compound under licensing is being developed in oral form to meet the new global challenges of the malaria incidence, including in India.
Artemisinin-based combination therapy has been recommended by the World Health Organisation (WHO) for the treatment of falciparum malaria.
CDRI, Lucknow, is a premier Research Institute of CSIR, Government of India.
IPCA is a Mumbai-based pharmaceutical company producing and exporting wide range of anti malarial compounds like choloroquine, amodiaquine, primaquine, artemether, arteether and artesunate and their formulations.
Shares of the company were last trading at Rs 651.30, up 0.85 per cent on the BSE.
The company has entered into a collaborative-cum-license agreement with CDRI for further developing its compound 99/411, a synthetic substitute for drugs based on Artemisinin derived from the plant artemisia annua, IPCA informed the BSE.
It would be a major break through in cost effective treatment of falciparum malaria and multi-drug resistant falciparum malaria in clinical practice, IPCA said.
The compound under licensing is being developed in oral form to meet the new global challenges of the malaria incidence, including in India.
Artemisinin-based combination therapy has been recommended by the World Health Organisation (WHO) for the treatment of falciparum malaria.
CDRI, Lucknow, is a premier Research Institute of CSIR, Government of India.
ADVERTISEMENT
IPCA is a Mumbai-based pharmaceutical company producing and exporting wide range of anti malarial compounds like choloroquine, amodiaquine, primaquine, artemether, arteether and artesunate and their formulations.
Shares of the company were last trading at Rs 651.30, up 0.85 per cent on the BSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
